At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top San Francisco based CFO’ operating in the Pharmaceutical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Executive Vice President and Chief Financial Officer of Exelixis
Chris Senner is Executive Vice President and Chief Financial Officer at Exelixis. Since July 2015, Mr. Senner has held this role with responsibility for ensuring the prudent management of the company’s assets, allowing Exelixis to invest in its proprietary and partnered molecules, launch new indications and otherwise advance its important work in the treatment of cancer. Prior to joining Exelixis, Mr. Senner served as Vice President, Corporate Finance at Gilead Sciences, Inc., which he joined in March 2010. At Gilead, he was accountable for controllership, tax, treasury and corporate and operational financial planning. Before joining Gilead, Mr. Senner spent 18 years at Wyeth in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth’s U.S. pharmaceuticals business and the BioPharma business unit. Mr. Senner holds a B.S. in Finance from Bentley College.
Follow Christopher Senner:
About Exelixis: Exelixis works is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases.
Jeffrey H. Cooper
Chief Financial Officer of Humanigen
Follow Jeffrey H. Cooper:
About Humanigen, Sierra Oncology: Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
Chief Financial Officer of 89bio
Ryan Martins is chief financial officer at 89bio.
Follow Ryan Martins:
About 89bio: 89Bio is a biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders.
CEO, Acting CFO of ProMed
Mr. Ronald Jabba serves as a Chief Executive Officer and Director at ProMed Inc.
Follow Ronald Jabba:
About ProMed, Zenflow: ProMed provides billing, credentialing, and contracting services in the healthcare sector.
Senior Vice President & Chief Financial Officer of Innoviva
Eric d’Esparbes is SVP and CFO at Innoviva. From 2010 to 2014, Mr. d’Esparbes served as the Chief Financial Officer of Joule Unlimited, a biotechnology company. Prior to Joule Unlimited, he was the Vice President, Finance, of AEI, a global emerging markets energy company. Eric arned a BAA in International Finance from the University of Montreal’s Hautes Etudes Commerciales in Montreal, Canada.
Follow Eric d’Esparbes:
About Innoviva: Innoviva is committed to building long-lasting value and improving patient care.
CFO of Inception Sciences
Zack McNealy joined Ventus Therapeutics as CFO in 2019.Zack McNealy is the Vice President, Finance responsible for Versant’s domestic and international management company entities. Zack also works extensively with a number of Versant’s biotech portfolio companies on their international structuring and operational setup. Zack joined Versant after spending seven years at Biotie Therapies (formerly Synosia Therapeutics) where he was Vice President, Finance supporting the U.S. and Swiss operations of the company. Prior to Biotie, Zack spent ten years at Johnson & Johnson as Plant Controller, Finance Manager and Financial Analyst. Zack received an MBA from the Wharton School, University of Pennsylvania and a BS in finance and accounting from Miami University (Ohio).
Follow Zack McNealy:
About Inception Sciences, Ventus Therapeutics: Inception Sciences creates therapies with transformative potential to address diseases and disorders with significant unmet need.
Chief Financial and Business Officer of Jasper Therapeutics
Jeet Mahal is the Chief Financial and Business Officer at Jasper Therapeutics.
Follow Jeet Mahal:
About Jasper Therapeutics: Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic.